|

SERD* + everolimus or capecitabine Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • UNC Lineberger Comprehensive Cancer Center1

Indications

  • Estrogen Receptor-positive Breast Cancer1
  • Hormone Receptor-Negative Breast Carcinoma1
  • Metastatic Breast Cancer1
  • Triple Negative Breast Cancer1
  • Breast Cancer1

Chapel Hill, North Carolina1 trial

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.